Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

Phase 4 Completed 19 enrolled University of Kansas Medical Center Pacira Pharmaceuticals, Inc · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

Timeline

Start: 2014-04
Primary completion: 2017-01
Completion: 2017-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupivacaine	Other / unclassified	266 mg	Other
Background	Ketorolac	Other / unclassified	30 mg	Intravenous

Indications

No indication recorded.